Monalizumab: inhibiting the novel immune checkpoint NKG2A
Abstract The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, allevia...
Main Authors: | Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Emilie Narni-Mancinelli, Sjoerd H. van der Burg, Eric Vivier |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-10-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0761-3 |
Similar Items
-
NKG2A/CD94 is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain
by: Gia-Gia T. Hò, et al.
Published: (2020-06-01) -
Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A
by: Niken M. Mahaweni, et al.
Published: (2018-12-01) -
SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway
by: Daria Bortolotti, et al.
Published: (2020-08-01) -
NKG2D Polymorphism in Melanoma Patients from Southeastern Spain
by: Lourdes Gimeno, et al.
Published: (2019-03-01) -
NKG2D Natural Killer Cell Receptor—A Short Description and Potential Clinical Applications
by: Jagoda Siemaszko, et al.
Published: (2021-06-01)